Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biosimilar symbols : Abbv save search
Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances
Published: 2024-02-14 (Crawled : 20:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.26%
H: 0.87%
C: 0.32%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.48%
H: 1.56%
C: 1.48%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.75%
H: 0.86%
C: 0.41%
biosimilar report global therapy growth market
Celltrion Healthcare announces the availability of Yuflyma a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.03%
H: 0.08%
C: -2.9%
humira biosimilar canada
Settlement Opens Doors for Biosimilars of Abbvie's Most Profitable Drug
Published: 2022-03-09 (Crawled : 15:30) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
drug set biosimilar
Celltrion Healthcare announces Canadian approval of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
health thc approval cel humira biosimilar
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Published: 2022-01-05 (Crawled : 16:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.32%
H: 3.3%
C: 2.1%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
humira fda fda acceptance biosimilar
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
Published: 2021-10-01 (Crawled : 20:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
fda biosimilar
Alvotech Announces Positive Top-Line Results for Switching Study Between Proposed Biosimilar AVT02 and Humira®
Published: 2021-09-09 (Crawled : 22:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.83%
H: 0.27%
C: -1.98%
positive results topline biosimilar
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.